These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36644312)

  • 1. The evidence base for emergency use authorizations for COVID-19 treatments: A rapid review.
    Knowlson C; Byrne A; Wilkinson J; Whitmore C; Torgerson D
    Health Sci Rep; 2023 Jan; 6(1):e1051. PubMed ID: 36644312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization.
    Huang DT; McCreary EK; Bariola JR; Wadas RJ; Kip KE; Marroquin OC; Koscumb S; Collins K; Shovel JA; Schmidhofer M; Wisniewski MK; Sullivan C; Yealy DM; Axe M; Nace DA; Haidar G; Khadem T; Linstrum K; Snyder GM; Seymour CW; Montgomery SK; McVerry BJ; Berry L; Berry S; Meyers R; Weissman A; Peck-Palmer OM; Wells A; Bart R; Albin DL; Minnier T; Angus DC
    Trials; 2021 May; 22(1):363. PubMed ID: 34034784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Emergency Use Authorizations (EUAs) During Pandemics: Double-edged Swords.
    Bhimraj A; Morgan RL; Shumaker AH; Lavergne V; Baden L; Cheng VC; Edwards KM; Gandhi RT; Gallagher JC; Muller WJ; O'Horo JC; Shoham S; Wollins DS; Falck-Ytter Y
    Clin Infect Dis; 2022 May; 74(9):1686-1690. PubMed ID: 34668010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.
    Rizk JG; Forthal DN; Kalantar-Zadeh K; Mehra MR; Lavie CJ; Rizk Y; Pfeiffer JP; Lewin JC
    Drug Discov Today; 2021 Feb; 26(2):593-603. PubMed ID: 33253920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents.
    Wolf J; Abzug MJ; Anosike BI; Vora SB; Waghmare A; Sue PK; Olivero RM; Oliveira CR; James SH; Morton TH; Maron GM; Young JL; Orscheln RC; Schwenk HT; Bio LL; Willis ZI; Lloyd EC; Hersh AL; Huskins CW; Soma VL; Ratner AJ; Hayes M; Downes K; Chiotos K; Grapentine SP; Wattier RL; Lamb GS; Zachariah P; Nakamura MM
    J Pediatric Infect Dis Soc; 2022 May; 11(5):177-185. PubMed ID: 35107571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of COVID-19 treatments among geriatric patients: a systematic review.
    Senderovich H; Vinoraj D; Stever M; Waicus S
    Ther Adv Infect Dis; 2022; 9():20499361221095666. PubMed ID: 35677110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19.
    Haddad F; Dokmak G; Karaman R
    Life (Basel); 2022 Nov; 12(11):. PubMed ID: 36362912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. US Food and Drug Administration (FDA) Emergency Use Authorization: Glass Half Full or Glass Half Empty?
    Guharoy R; Krenzelok EP
    Clin Infect Dis; 2021 Aug; 73(3):549-552. PubMed ID: 33104216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The FDA and the COVID-19: A political economy perspective.
    March RJ
    South Econ J; 2021 Apr; 87(4):1210-1228. PubMed ID: 33821046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
    JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health Equity and Access to COVID-19 Treatments Available through Emergency Use Authorizations.
    Johnson C; Wolff C; Xu J;
    J Racial Ethn Health Disparities; 2024 Jul; ():. PubMed ID: 39039261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
    Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R
    Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review comparing at-home diagnostic tests for SARS-CoV-2: Key points for pharmacy practice, including regulatory information.
    Kepczynski CM; Genigeski JA; Koski RR; Bernknopf AC; Konieczny AM; Klepser ME
    J Am Pharm Assoc (2003); 2021; 61(6):666-677.e2. PubMed ID: 34274214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Remdesivir in the Management of COVID-19: A Systematic Review on Current Evidences.
    Nasir M; Talha KA; Islam T; Saha SK; Selina F; Parveen RA
    Mymensingh Med J; 2020 Apr; 29(2):481-487. PubMed ID: 32506110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA Thresholds.
    Larkey NE; Ewaisha R; Lasho MA; Roforth MM; Granger D; Jerde CR; Wu L; Gorsh A; Klassen SA; Senefeld JW; Joyner MJ; Baumann NA; Theel ES; Mills JR
    Microbiol Spectr; 2022 Aug; 10(4):e0115422. PubMed ID: 35862939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy in COVID-19; A narrative review for emergency providers.
    Mehta N; Mazer-Amirshahi M; Alkindi N; Pourmand A
    Am J Emerg Med; 2020 Jul; 38(7):1488-1493. PubMed ID: 32336586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2.
    Nathan R; Shawa I; De La Torre I; Pustizzi JM; Haustrup N; Patel DR; Huhn G
    Infect Dis Ther; 2021 Dec; 10(4):1933-1947. PubMed ID: 34374951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory therapies for COVID-19.
    Mathur P; Kottilil S
    Front Med (Lausanne); 2022; 9():921452. PubMed ID: 35991665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.